Miscellaneous hematological agents:
Indications for: ADAKVEO
To reduce the frequency of vaso-occlusive crises (VOCs) in sickle cell disease.
Give by IV infusion over 30mins. ≥16yrs: 5mg/kg at Week 0, Week 2, and every 4 weeks thereafter.
<16yrs: not established.
Monitor for infusion-related reactions. Discontinue if severe infusion-related reactions occur; treat appropriately. Interrupt or slow infusion rate if mild to moderate infusion-related reactions occur; treat symptomatically. Consider premedication and/or reduced infusion rate for subsequent infusions. Pregnancy. Nursing mothers.
Caution with corticosteroids, unless indicated (eg, treating anaphylaxis). Interferes with automated platelet counts (esp. when collected in tubes containing EDTA) that may lead to unevaluable or falsely decreased platelet counts; run tests within 4hrs of collection or collect in citrate tubes instead.
Nausea, arthralgia, back pain, abdominal pain, pyrexia; infusion-related reactions.
Generic Drug Availability:
Single-dose vial (10mL)—1